At present, the only biological agent approved for clinical use in China is infliximab, a medication that mainly targets soluble and transmembrane tumor necrosis factor (TNF)-α, which is a powerful proinflammatory cytokine that plays a role in the dysregulation of the mucosal immune response in IBD (30). Here, TNF is linked to inflammatory bowel disease.